Global Markets Direct’s, 'Lung Cancer - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Lung Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lung Cancer. Lung Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
A snapshot of the global therapeutic scenario for Lung Cancer.
A review of the Lung Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
Coverage of products based on various stages of development ranging from discovery till registration stages.
A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
Coverage of the Lung Cancer pipeline on the basis of route of administration and molecule type.
Key discontinued pipeline projects.
Latest news and deals relating to the products.
Reasons to buy
Identify and understand important and diverse types of therapeutics under development for Lung Cancer.
Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
Devise corrective measures for pipeline projects by understanding Lung Cancer pipeline depth and focus of Indication therapeutics.
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Boehringer Ingelheim GmbH Kyowa Hakko Kirin Co., Ltd. Amgen Inc. Sanofi-Aventis AstraZeneca PLC Eli Lilly and Company Viralytics Ltd. Seattle Genetics, Inc. Inovio Biomedical Corporation Bavarian Nordic A/S Gilead Sciences, Inc. Biotest AG Merck & Co., Inc. A&G Pharmaceutical, Inc. ViaCord Amorfix Life Sciences Ltd. Ipsen S.A. Aposense Ltd. Millennium Pharmaceuticals, Inc. Astellas Pharma Inc. CK Life Sciences Int'l., (Holdings) Inc. Daewoong Pharmaceutical Co., Ltd. Les Laboratoires Servier Nippon Kayaku Co., Ltd. SuperGen, Inc. Taiho Pharmaceutical Co., Ltd. Santaris Pharma A/S Menarini Group AntiCancer, Inc. 4SC AG Momenta Pharmaceuticals, Inc. ValiRx Plc IMMUNOMEDICS, INC Ariad Pharmaceuticals, Inc. Lorus Therapeutics Inc Bionomics Limited Orchid Chemicals & Pharmaceuticals Ltd Patrys Limited ARQULE, INC Cytokinetics, Inc Telik, Inc. CytRx Corporation Pharmacyclics, Inc. Dendreon Corporation ProMetic Life Sciences Inc. Progen Pharmaceuticals Limited Sareum Holdings plc Microbio Co., Ltd. Rexahn Pharmaceuticals, Inc. Scancell Holdings Plc Nanobiotix Antisense Pharma GmbH Chipscreen Biosciences Ltd CIMAB S.A. Supratek Pharma Inc. Bionucleon Srl Actis Biologics, Inc Med Discovery SA Hutchison MediPharma Limited Alethia Biotherapeutics Inc. Ascenta Therapeutics, Inc. Gene Signal International SA. OncoMed Pharmaceuticals, Inc. Five Prime Therapeutics, Inc. Kalos Therapeutics, Inc. PanaGin Pharmaceuticals Inc. GP Pharm, S.A. Merrimack Pharmaceuticals, Inc. Deciphera Pharmaceuticals, LLC BioCancell Therapeutics, Inc. Omnitura Therapeutics Inc. Pharminox Limited Mirna Therapeutics, Inc. Transtech Pharma, Inc. Welichem Biotech Inc. NewLink Genetics Corporation Cellceutix Corporation PharmaMar, S.A. TVAX Biomedical, LLC Biokine Therapeutics Ltd. Genelux Corporation Viventia Biotechnologies Inc. Kuhnil Pharmaceutical Co., Ltd. Advanced Cancer Therapeutics Sunshine Biopharma, Inc. ISU ABXIS Co.,Ltd. Bioo Therapeutics Ensoltek Co., Ltd. Almac Discovery Ltd. RaQualia Pharma Inc.